Introduction {#S0001}
============

Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation and an increased inflammatory response of the airways.[@CIT0001] However, beyond the airways, COPD is a complex and heterogeneous respiratory disease involving multi-organ inflammation. Although the mechanisms are yet to be investigated in detail, chronic inflammation in COPD and comorbidities accelerate the natural progression of one another.[@CIT0001] Therefore, systemic comorbidities of COPD are important challenges in reducing future risks of mortality and exacerbation, which are the main treatment goals in COPD.

A recent study investigated the prevalence and severity of non-alcoholic fatty liver disease (NAFLD), defined by a noninvasive surrogate for the diagnosis of fatty liver, in patients with COPD and showed a close association between NAFLD and COPD.[@CIT0002] The prevalence of simple steatosis, non-alcoholic steatohepatitis, and fibrotic liver were 41%, 37%, and 61%, respectively, in patients with COPD. Because NAFLD is primarily linked with metabolic comorbidities of COPD and systemic inflammation,[@CIT0002] the authors insisted that NAFLD should be included among COPD comorbidities, and hypothesized that COPD progression in NAFLD might be attributable to oxidative stress and systemic inflammation. Moreover, several studies reported a significant association between NAFLD and decreased lung function in the general population.[@CIT0003]--[@CIT0007] However, detailed underlying mechanisms still remain unresolved.

Fibrosis-4 index (FIB-4), a noninvasive, simple-to-use equation, which includes laboratory and clinical variables such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), platelet count, and age as constituent variables, was proposed to evaluate the degree of liver fibrosis in patients with chronic liver diseases.[@CIT0008],[@CIT0009] FIB-4 has proven to be a significant prognostic predictor for the development of hepatocellular carcinoma in patients with chronic liver diseases.[@CIT0010]--[@CIT0012] Besides evaluating chronic liver diseases, FIB-4 has been used to assess liver fibrosis and its relation with other systemic inflammatory diseases or conditions, including arterial stiffness/abnormal central hemodynamics in heart failure, cerebral white matter hyperintensity, rheumatoid arthritis, and polyangiitis.[@CIT0013]--[@CIT0017]

Accordingly, we investigated whether liver fibrosis assessed using FIB-4 is associated with all-cause mortality in patients with COPD, based on the concept that liver fibrosis might be a sequela of hepatic or systemic inflammation.

Methods {#S0002}
=======

Study Subjects {#S0002-S2001}
--------------

We extracted the details of 1,282 patients who were diagnosed COPD based on the 10th revision of the International Statistical Classification of diseases and Related Health Problems (ICD-10) codes and medications prescribed from January 2006 to December 2010 in Severance Hospital, South Korea.

The inclusion criteria were, (1) age ≥ 40 years; (2) ICD-10 codes for COPD or emphysema (J43.0x-J44.x, with the exception of J43.0 as primary or secondary (within the fifth position) diagnosis); and (3) use of more than one of the following COPD medications at least twice per year, long-acting muscarinic antagonist, long-acting beta-2 agonist (LABA), inhaled corticosteroid + LABA, short-acting muscarinic antagonist (SAMA), short-acting beta-2 agonist (SABA), SAMA + SABA, phosphodiesterase-4 inhibitor, systemic beta-agonist, or methylxanthine.

However, 84 patients without pulmonary function information, 57 patients without obstructive pulmonary function, 312 patients with a history of asthma, and 73 patients with chronic liver disease were excluded as they failed to fulfill inclusion criteria ([Figure 1](#F0001){ref-type="fig"}). Finally, 756 patients with COPD were enrolled and their medical records were retrospectively reviewed until 2018. Index date from when the patients were followed up was defined as the date of the first COPD medication prescribed to the patients.Figure 1Flow chart for the selection of the study population. A total of 1282 patients with suspected COPD were considered eligible. Of these, 453 patients without PFT results, history of asthma, and not COPD were excluded. Then, 73 patients with known chronic liver diseases were further excluded. Finally, 756 patients with COPD were selected for the statistical analysis.**Abbreviations:** COPD, chronic obstructive pulmonary disease; PFT, pulmonary function test.

The study protocol was consistent with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Institutional Review Board (IRB) of Severance University. The requirement for an informed consent was waived on the acknowledgement of IRB of Severance University, due to the reason that data given to researchers are anonymized with no identifying information available. Study data are available upon request, so any interested researchers can access and share the data by submitting a request and receiving the permission from the corresponding author and IRB of Severance University. The data will be provided anonymously.

Exacerbation {#S0002-S2002}
------------

COPD exacerbation was defined as a ≥ 2-day aggravation of one of the following three symptoms (cough, sputum, and dyspnea) resulting in an unscheduled hospital visit, a requirement of antibiotics and/or oral corticosteroids, or hospitalization for additional treatment.

Assessment of Liver Fibrosis {#S0002-S2003}
----------------------------

FIB-4 was calculated using the following equation: age (years) × aspartate aminotransferase (AST) (IU/L)/\[platelet count (10^9^/L) × √alanine aminotransferase (ALT) (IU/L)\]. The study population was divided into three risk groups, low (Q1; (≤1.05)), intermediate (Q2-3), and high (Q4; (\>1.57)) FIB-4 groups.

Statistical Analysis {#S0002-S2004}
--------------------

Categorical variables between the two groups were analyzed using the *χ*^2^ test and were expressed as number and percentage. Continuous variables between the two groups were compared using Student's *t*-test and were expressed as mean ± standard deviation. The predictive role of FIB-4 for all-cause mortality was described as hazard ratio (HR) using the multivariate Cox hazards model analysis and  Kaplan-Meier curve. The risk of exacerbation is described as the odds ratio (OR) with 95% confidence interval (CI) using generalized estimating equations for longitudinal data of exacerbation. P-value of \<0.05 was considered to be statistically significant. All statistical analyses were conducted using SPSS software version 25 (SPSS, Chicago, IL).

Results {#S0003}
=======

Baseline Characteristics {#S0003-S2001}
------------------------

The baseline characteristics of the enrolled 756 patients with COPD at the time of diagnosis are shown in [Table 1](#T0001){ref-type="table"}. The mean age was 67.9 years with a predominance of male patients (85.1%). Among the underlying comorbidities, hypertension was the most common (33.6%), followed by malignancy (20.1%) and diabetes mellitus (17.3%). Most patients with COPD were ever smokers (82.5%). The initial pulmonary function test results showed a mean FEV~1~ of 1.39 L (57% of predicted), mean FVC of 2.48 L (69.9% of predicted), and mean FEV~1~/FVC ratio of 56.1%. The mean FIB-4 was 1.53.Table 1Baseline Characteristics at the Time of COPD Diagnosis (n=756)VariablesValuesDemographic Variables Age, years67.9 ± 8.9 Sex, male643 (85.1) Body mass index, kg/m^2^22.5 ± 3.2Comorbidities Malignancy152 (20.1) Cerebral vascular disease67 (8.9) Coronary artery occlusive disease113 (14.9) Congestive heart failure93 (12.3) Chronic kidney disease54 (7.1) Diabetes mellitus131 (17.3) Hypertension254 (33.6) Bronchiectasis69 (9.1) Destroyed lung47 (6.2)Smoking (n=731) Ever smoker603 (82.5) Never smoker128 (17.5)Pulmonary Function Test Variables FEV~1~, L1.39 ± 0.52 FEV~1~, % predicted57.0 ± 18.9 FVC, L2.48 ± 0.79 FVC, % predicted69.9 ± 18.6 FEV~1~/FVC, %56.1 ± 10.1Laboratory Variables Hemoglobin, g/dL13.7 ± 1.7 Platelet count, ×1000/μL270.2 ± 93.8 Erythrocyte sedimentation, mm/hr41.0 ± 36.1 C-reactive protein, mg/L23.8 ± 48.5 Serum albumin, g/dL4.2 ± 0.5 Blood urea nitrogen, mg/dL16.5 ± 7.9 Serum creatinine, mg/dL1.05 ± 0.33 Aspartate aminotransferase, IU/L24.9 ± 23.3 Alanine aminotransferase, IU/L23.2 ± 21.5 Total bilirubin, mg/dL0.7 ± 1.1FIB-41.53 ± 1.20[^1][^2]

Comparison Between Survivors and Non-Survivors {#S0003-S2002}
----------------------------------------------

During the study period (mean follow-up, 6.1 years), 174 (23.1%) patients died, whereas 582 (76.9%) were alive. When the baseline characteristics were compared ([Table 2](#T0002){ref-type="table"}), non-survivors were significantly older (mean 71.3 years vs 66.9 years, P\<0.001) and had a higher proportion of males (91.4% vs 83.2%, P=0.007) and those with smoking history (89.7% vs 80.3%, P=0.004) than survivors. Various comorbidities including malignancy, cerebral vascular disease, coronary artery occlusive disease (CAOD), congestive heart failure, chronic kidney disease, diabetes mellitus, and hypertension were more frequently observed in non-survivors than in survivors (all P\<0.05). Among pulmonary function test results, FEV~1~ (mean 1.32 L vs 1.41 L, P=0.044), FVC (mean 2.36 L vs 2.52 L, P=0.013), and FVC % predicted (67.1% vs 70.8%, P=0.017) were significantly lower in non-survivors than in survivors. The FIB-4 was significantly higher in non-survivors than in survivors (mean 1.8 vs 1.4, P\<0.001).Table 2Comparison Between Survivors and Non-SurvivorsVariablesSurvivors (n=582, 76.9%)Non-Survivors (n=174, 23.1%)P-valueDemographic Variables Age, years66.9 ± 9.171.3 ± 7.9\<0.001 Sex, male484 (83.2)159 (91.4)0.007 Body mass index, kg/m^2^22.6 ± 3.222.4 ± 3.40.554Comorbidities Malignancy84 (14.4)68 (39.1)\<0.001 Cerebral vascular disease42 (7.2)25 (14.4)0.006 Coronary artery occlusive disease9 (11.9)44 (25.3)\<0.001 Congestive heart failure58 (10.0)35 (20.1)0.001 Previous tuberculosis131 (22.5)44 (25.3)0.474 Chronic kidney disease33 (57)21 (12.1)0.007 Diabetes mellitus89 (15.3)42 (24.1)0.009 Hypertension179 (30.8)75 (43.1)0.003 Bronchiectasis58 (10.0)11 (6.3)0.177 Destroyed lung35 (6.0)12 (6.9)0.720Smoking (n=731) Ever smoker447/557 (80.3)156/174 (89.7)0.004 Never smoker110/557 (19.7)18/174 (10.3)Pulmonary Function Test Variables FEV~1~, L1.41 ± 0.531.32 ± 0.460.044 FEV~1~, % predicted57.4 ± 19.355.7 ± 17.80.281 FVC, L2.52 ± 0.812.36 ± 0.730.013 FVC, % predicted70.8 ± 18.967.1 ± 17.40.017 FEV~1~/FVC, %56.2 ± 10.455.7 ± 9.40.526Laboratory Variables Hemoglobin, g/dL13.8 ± 1.713.4 ± 1.80.066 Platelet count, ×1000/μL268.8 ± 90.3273.7 ± 106.10.558 Eosinophil,/μL251 ± 267225 ± 2290.283 Eosinophil, %3.2 ± 2.92.9 ± 2.80.329 Erythrocyte\
 sedimentation, mm/hr37.2 ± 32.951.6 ± 42.50.057 C-reactive\
 protein, mg/L21.0 ± 47.328.9 ± 50.40.124 Serum albumin, g/dL4.3 ± 0.54.1 ± 0.60.006 Blood urea\
 nitrogen, mg/dL15.9 ± 6.818.1 ± 10.30.054 Serum\
 creatinine, mg/dL1.01 ± 0.291.14 ± 0.410.005 Aspartate\
 aminotransferase,\
 IU/L24.2 ± 17.927.0 ± 35.80.321 Alanine\
 aminotransferase,\
 IU/L22.8 ± 16.224.8 ± 33.50.452 Total bilirubin, mg/dL0.6 ± 0.30.9 ± 2.10.219FIB-41.4 ± 0.81.8 ± 2.0\<0.001[^3][^4]

Multivariate Cox Hazard Analysis for All-Cause Mortality {#S0003-S2003}
--------------------------------------------------------

Multivariate Cox hazard analysis to identify the independent predictors of all-cause mortality is shown in [Table 3](#T0003){ref-type="table"}. Older age (HR=1.05, 95% CI 1.03--1.07), underlying malignancy (HR=2.94, 95% CI 2.15--4.02), CAOD (HR=1.58, 95% CI 1.10--2.26), higher GOLD stage (HR=1.26, 95% CI 1.02--1.56), and higher FIB-4 (HR=1.15, 95% CI 1.03--1.27) were significantly associated with the increased risk of all-cause mortality (all P\<0.05), whereas higher body mass index (HR=0.95, 95% CI 0.89--0.99) was independently protective for all-cause mortality (all P\<0.05).Table 3Multivariate Cox Hazard Model to Identify Independent Predictors of All-Cause MortalityVariablesHazard Ratio95% CIP-valueDemographic Variables Age, years1.051.03--1.07\<0.001 Sex, male1.670.94--2.940.080 Body mass index, kg/m^2^0.950.89--0.990.031Comorbidities Malignancy2.942.15--4.02\<0.001 Cerebral vascular disease1.280.82--1.990.274 Coronary artery occlusive disease1.581.10--2.260.013 Chronic kidney disease1.380.84--2.250.205 Diabetes mellitus1.290.88--1.880.187 Hypertension1.100.78--1.560.570Pulmonary Function Test Variables GOLD stage, as one stage increases1.261.02--1.560.036FIB-41.151.03--1.270.010[^5]

The study population was stratified into three risk groups (low \[Q1\], intermediate \[Q2-3\], and high \[Q4\] FIB-4 groups). The high FIB-4 group (\>1.57) had a significantly lower cumulative survival rate than the low FIB-4 group (≤1.05) (P=0.031, Log-rank test) ([Figure 2](#F0002){ref-type="fig"}).Figure 2The cumulative survival rate according to FIB-4. When the study population was stratified into three risk groups (low \[Q1\], intermediate \[Q2-3\], and high \[Q4\] FIB-4 groups), the high FIB-4 (\>1.57) group had a significantly lower cumulative survival rate than the low FIB-4 (≤1.05) group (P=0.031, Log-rank test).**Abbreviation:** FIB-4, fibrosis-4 index.

Multivariate Regression Analysis for the Relationship Between FIB-4 and Acute Exacerbation {#S0003-S2004}
------------------------------------------------------------------------------------------

The number of patients who had ever experienced acute exacerbation during the follow-up duration was 468 (61.9%), and the mean number of acute exacerbations of COPD per year was 0.42 in this study. On multivariate regression analyses ([Table 4](#T0004){ref-type="table"}), higher GOLD stage (OR=1.19, 95% CI 1.07--1.34) was independently associated with the increased risk of acute exacerbation, whereas higher FIB-4 (HR=1.05, 95% CI 1.01--1.15) was independently associated with the increased risk of acute exacerbation (all P\<0.05).Table 4Multivariate Regression Analysis for the Relationship Between FIB-4 and Acute ExacerbationVariablesOdds Ratio95% CIP-valueAge, years0.990.98--1.010.277Sex, male1.210.93--1.590.155Body mass index, kg/m^2^1.010.99--1.030.501GOLD stage, as one stage increases1.191.07--1.340.002FIB-41.081.01--1.150.034[^6]

Discussion {#S0004}
==========

Based on the hypothesis that liver fibrosis, a sequela of hepatic or systemic inflammation, may act as an unfavorable prognostic factor in patients with COPD, we investigated the relationship between fibrotic burden in liver and COPD. Towards this, we used FIB-4 and various clinical outcomes, including all-cause mortality and acute exacerbations in patients with COPD. Finally, we found that higher FIB-4 independently predicted the higher risk of all-cause mortality and acute exacerbations. In addition, the higher FIB-4 group showed a significantly lower cumulative survival than the low FIB-4 group. The cutoff of FIB-4 to defined higher FIB-4 group in this study was 1.57, which is quite similar to the established cutoff of 1.45 indicating the presence of significant liver fibrosis (≥ stage 2 fibrosis).[@CIT0008]

COPD is a complex respiratory disease with systemic inflammation frequently accompanying various comorbidities such as cardiovascular disease, lung cancer, metabolic syndrome, depression, and dysfunctional skeletal myopathy.[@CIT0018],[@CIT0019] All these comorbidities impact on prognosis, quality of life, and physical activities of patients with COPD, and play a major role in the classification of the various phenotypes of COPD. Interest regarding liver diseases in patients with COPD has been increasing recently. NAFLD is highly prevalent and is considered as one of the contributors of cardio-metabolic comorbidities in patients with COPD.[@CIT0020] According to a recent meta-analysis, NAFLD is strongly associated with reduced pulmonary function. Reduced lung volumes at baseline were also associated with increased NAFLD incidence, especially in Asians.[@CIT0006] However, only a few studies have investigated how fibrotic burden in the liver impacts the outcomes of patients with COPD.[@CIT0018],[@CIT0021]

Divo et al investigated various comorbidities and their influence on the risk of mortality in patients with COPD.[@CIT0018] Although the prevalence of liver cirrhosis was lower than that of cardiovascular and metabolic diseases, liver cirrhosis was significantly associated with the increased risk for death.[@CIT0018] Contrarily, our current study recruited only patients with a milder fibrotic burden in the liver after excluding those with known liver disease. Nevertheless, subtle or subclinical fibrosis progression in the liver, reflected by a higher FIB-4, was independently associated with a higher risk of mortality and acute exacerbation. This might mean that fibrotic burden in the liver might have a prognostic implication in patients with COPD. Indeed, in a recent longitudinal study, it was evident that liver fibrosis, not just liver steatosis, was independently associated with long-term overall mortality in patients with NAFLD.[@CIT0022] This issue is further supported by Viglino et al who reported a three-fold higher risk of developing the first cardiovascular event and death in patients with COPD with co-existing liver fibrosis---assessed using another non-invasive patented surrogate, FibroTest^®^---when compared to those without liver fibrosis.[@CIT0021],[@CIT0023]

Several comorbidities are associated with increased risk of acute exacerbation in patients with COPD, such as gastro-esophageal reflux disease, anxiety, depression, pulmonary embolism, pulmonary hypertension, and cardiovascular disease.[@CIT0001] In addition to previously known comorbidities, higher FIB-4 was independently associated with the increased risk of acute exacerbation in our current study. In contrast, liver disease did not impact the rate of acute exacerbations in the study by Viglino et al, with only a severe level of exacerbation noted in emergency admission, hospitalization, and the intensive care unit.[@CIT0021] The authors demonstrated a tendency of an increase in the risk of acute exacerbation-related hospitalization in those with liver fibrosis (P=0.06). We included both moderate and severe exacerbation cases; however, increased FIB-4 was not associated with each type of exacerbation (data not shown). Moreover, airflow limitation was less severe among the participants of the study by Viglino et al, resulting in a lower proportion of patients who had experienced at least one exacerbation in contrast to that in our study (45.9% vs 61.9%).

There are several common pathophysiologic mechanisms shared between COPD and liver fibrosis. First, COPD and liver fibrosis are characterized by similar inflammatory processes involving tumor necrosis factor-alpha, transforming growth factor-beta, leptin, and adiponectin.[@CIT0024]--[@CIT0029] These pro-inflammatory mediators promote tissue damage and remodeling in the lung and contribute to the progression of liver fibrosis. In addition, chronic intermittent hypoxia induces liver fibrosis through several pathways. In the study on rodent models of sleep apnea, Toll-like receptor 4-mediated mitogen-activated protein kinase and nuclear factor-kB signaling were related to increased liver fibrosis.[@CIT0030] Moreover, hepatocyte hypoxia-inducible factor-1 induced liver fibrosis in a mouse model of NAFLD due to liver tissue hypoxia in hepatic steatosis.[@CIT0031] Thirdly, the process of aging has been considered as a risk factor for the development and progression of COPD and liver fibrosis. Aging is generally related with increased oxidative stress and reduced tolerance to oxidative damage.[@CIT0032] Moreover, immunosenescence is unavoidable with increasing age, resulting in various clinical consequences including increased susceptibility to infection, malignancy, and autoimmunity.[@CIT0033],[@CIT0034] Increased inflammatory reaction mainly composed of CD4^+^ lymphocytes and macrophages expressing T~H~2 cytokines is the main factor involved in the higher susceptibility to liver fibrosis with increasing age.[@CIT0035] Increased CD4^+^ and CD8^+^ T cells in the airway and lung parenchyma are also major COPD-related changes.[@CIT0036]

This study has several limitations. Firstly, because of the absence of a control group, we were not able to assess the impact of liver fibrosis on the clinical outcomes in COPD compared to that in a control group. In addition, the degree of liver fibrosis was noninvasively assessed using FIB-4 without detailed histological information. However, the simple-to-use FIB-4 has been validated and widely used to assess the degree of liver fibrosis and cirrhosis in chronic liver disease.[@CIT0008]--[@CIT0010] Thirdly, NAFLD is a major liver disease that progresses to liver fibrosis, and metabolic syndrome is an essential comorbidity that contributes to the progression of liver fibrosis. Unfortunately, NAFLD and metabolic syndrome presence-related data were not available for this study. Lastly, because of the unavailability of data on cause of death, only all-cause mortality was assessed, and thus, the effect of liver fibrosis on mortality from COPD was not evaluated.

Conclusion {#S0005}
==========

A higher fibrotic burden assessed using FIB-4 at the diagnosis of COPD was independently predictive of the increased risk of all-cause mortality and acute exacerbation in patients with COPD without chronic liver diseases. FIB-4, a non-invasive, simple-to-use, and readily available tool in daily clinical practice, could play a role as a prognostic tool representing liver fibrosis in patients with COPD.
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[^1]: **Note:** Values are expressed as mean ± standard deviation or number (%).

[^2]: **Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; FIB-4, fibrosis-4 index.

[^3]: **Note:** Values are expressed as mean ± standard deviation or number (%).

[^4]: **Abbreviations:** FEV~1~, forced expiratory volume in 1 s; FVC, forced vital capacity; FIB-4, fibrosis-4 index.
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